Application of Baihu decoction in preparation of medicine for treating hashimoto thyroiditis
By using the preparation method of Baihu Decoction, the raw materials such as Agnesium, gypsum, licorice and japonica rice were used to alleviate the damage of thyroid follicular cells induced by TgAb, and the problem of lack of a cause-based treatment plan in Hashimoto's treatment of thyroiditis was solved, and the problem of lack of a treatment plan for the cause was achieved. Protective and inflammatory regulation of thyroid function.
Patent Information
- Application Number
- CN202411218909.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-02
- Publication Date
- 2024-12-03
AI Technical Summary
The existing treatment methods for Hashimoto's thyroiditis lack treatment plans for the cause, and the effectiveness of traditional Chinese medicine prescriptions in clinical applications has not been fully discussed.
Using the application of Baihu Decoction in preparation, the combination and decoction process of raw materials such as Agnesium, gypsum, licorice and japonica rice was prepared with a concentration of 80-120μg/ml to relieve TgAb-induced thyroid follicular cells. Injuries such as proliferation inhibition, apoptosis and overexpression of inflammatory factors.
Baihu Decoction significantly reduced the apoptosis rate of thyroid follicular cells, increased the secretion level of T4, and reduced the expression of the inflammatory factor IL-6, providing a new idea for the treatment of Hashimoto's thyroiditis.
Smart Images

Figure CN119055729A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of medical use, and in particular relates to the application of Baihu decoction in preparing a medicine for treating Hashimoto's thyroiditis. Background Art
[0002] Hashimoto thyroiditis (HT) is an autoimmune disease of the thyroid gland with individual genetic susceptibility and environmental factors. Its pathological characteristics are mainly a large number of lymphocyte infiltration in the thyroid tissue. In the late stage, thyroid gland atrophy and even loss of thyroid function can be seen. The incidence of HT is about 3%-15%, and female patients are far more than 6-9 times the number of male patients. It is common, multiple, and has a long course of disease.
[0003] The key to the treatment of HT is to control inflammation, with the goal of regulating the body's immunity, reducing inflammatory responses, and improving thyroid function. However, since the pathogenic mechanism of HT is still unclear, there is currently no treatment method targeting the cause. Clinical treatment plans often use symptomatic treatment with antithyroid drugs and glucocorticoids. In the diagnosis and treatment of clinical diseases, Chinese medicine's syndrome differentiation and treatment are similar to targeted treatments, and its prescriptions and medicines have definite efficacy and few toxic side effects. Therefore, it is an urgent problem to be solved in the current research stage to clarify the effective prescriptions and medicines of Chinese medicine in the treatment of Hashimoto's thyroiditis and explore the significance of its principles, methods and prescriptions. Summary of the invention
[0004] In view of this, the purpose of the present invention is to provide the use of Baihu Decoction in the preparation of a drug for treating Hashimoto's thyroiditis. The Baihu Decoction can relieve TgAb-induced thyroid follicular cell proliferation inhibition, apoptosis, cell migration and overexpression of inflammatory factors and other damages, and can regulate the level of T4 secretion. This research finding can provide new ideas for the later treatment of HT.
[0005] To achieve the above object, the present invention provides the following technical solutions:
[0006] The invention provides application of Baihu decoction in preparing medicine for treating Hashimoto's thyroiditis. The crude drug concentration of the Baihu decoction is 80-120 μg / ml.
[0007] Preferably, the Baihu decoction comprises the following raw material components in parts by weight:
[0008] 10-15 parts of Anemarrhena asphodeloides, 30-35 parts of Gypsum, 3-5 parts of Licorice, and 10-15 parts of Japonica rice.
[0009] Preferably, the preparation method of Baihu Decoction comprises the following steps:
[0010] (1) Mixing Rhizoma Anemarrhenae, Gypsum, Licorice and glutinous rice, soaking them in water, and boiling them to obtain a primary extract and a medicinal residue;
[0011] (2) mixing the medicinal residue with water and decocting the mixture twice to obtain a decoction;
[0012] (3) The primary extract and the decoction are combined and concentrated to obtain a medicinal solution.
[0013] Preferably, the amount of water added in step (1) is 7.5 to 10 times the weight of the impregnated medicinal material.
[0014] Preferably, the immersion time in step (1) is 20 to 40 minutes, and the immersion temperature is 20 to 25°C.
[0015] Preferably, the decocting time in step (1) is 50 to 70 minutes, and the decocting temperature is 120 to 160°C.
[0016] Preferably, the volume ratio of the medicinal residue to water in step (2) is 1:2-3.
[0017] Preferably, the time for the secondary decoction in step (2) is 20 to 30 minutes, and the temperature for the secondary decoction is 90 to 110°C.
[0018] Preferably, the concentration time in step (3) is 20 to 30 minutes, and the concentration temperature is 80 to 90°C.
[0019] The invention provides application of Baihu decoction in preparing medicine for treating thyroid cell damage.
[0020] Compared with the prior art, the present invention has the following beneficial effects:
[0021] In this study, a thyroid follicular epithelial cell injury model was established by in vitro cell culture, and a "blank control group" and a "model control group" were set up. The viability, apoptosis rate, cell migration and repair ability, and the expression of inflammatory cytokines IL-6 (interleukin-6) and T4 (tetraiodothyronine) of Nthy-ori3-1 cells in the two groups were compared and determined by MTT colorimetry, Annexin V-FITC staining combined with flow cytometry, cell scratch test, indirect immunofluorescence test, ELISA and other methods. The results showed that TgAb could inhibit the viability of thyroid follicular epithelial cells and induce excessive apoptosis; the migration ability of thyroid follicular epithelial cells under the action of TgAb was significantly lower than that of normal thyroid follicular epithelial cells; in addition, compared with the normal group, the inflammatory cytokine IL-6 in the thyroid follicular epithelial cells treated with TgAb was overexpressed and the actual content of secreted T4 was significantly reduced. The above results show that TgAb induces inflammatory damage in Nthy-ori3-1 cells, inhibits cell proliferation, growth and migration, promotes cell apoptosis and the expression of inflammatory cytokines, and stimulates the inflammatory response of thyroid follicular cells. This shows that the present invention has preliminarily successfully established a TgAb-induced thyroid follicular cell inflammatory damage model.
[0022] The present invention establishes a model of TgAb-induced human thyroid follicular epithelial cell damage based on in vitro cell culture, the purpose of which is to confirm that TgAb is the main pathogenic factor of Hashimoto's thyroiditis, and to preliminarily explore the mechanism of action of TgAb on HT, and to find out the effective prescriptions for treating HT in "Treatise on Febrile and Miscellaneous Diseases". Among them, Baihu Decoction has a significant protective effect on the thyroid follicular epithelial cell damage model, can reduce the occurrence of cell apoptosis, increase the level of thyroxine T4, reduce the expression of inflammatory factor IL-6 and the large-area migration of inflammatory tissue.
[0023] Experiments have shown that TgAb can affect the growth and proliferation of thyroid follicular cells cultured in vitro, significantly reducing cell viability and apoptosis rate, further proving that TgAb is the main pathogenic factor leading to thyroid inflammation in HT. Baihu decoction can alleviate TgAb-induced damage to thyroid follicular cells such as proliferation inhibition, apoptosis, cell migration, and overexpression of inflammatory factors, and can regulate T4 secretion levels. The above research findings can provide new ideas for the later treatment of HT. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 The dose-effect relationship of different concentrations of TgAb on the damage rate of Nthy-ori 3-1 cells;
[0025] Figure 2 is the time-effect relationship between TgAb and the injury rate of Nthy-ori 3-1 cell model, where “****” represents P < 0.0001;
[0026] Figure 3 The cell migration rate results in Section 1.4 of Example 1, where “**” represents P < 0.05;
[0027] Figure 4 The cell migration rate results after 0 h of culture in Section 1.4 of Example 1, wherein the left picture is an inverted phase contrast microscope picture of the control group, and the right picture is an inverted phase contrast microscope picture of the model group;
[0028] Figure 5 The cell migration rate results after 24 h of culture in Section 1.4 of Example 1, wherein the left picture is an inverted phase contrast microscope picture of the control group, and the right picture is an inverted phase contrast microscope picture of the model group;
[0029] Figure 6 The cell morphology diagram of Part 1.5 of Example 1 observed by an inverted phase contrast microscope at a magnification of 200 times, wherein the left picture is the blank group and the right picture is the model group;
[0030] Figure 7 The cell morphology diagram of Part 1.5 of Example 1 observed by an inverted phase contrast microscope at a magnification of 400 times, wherein the left picture is the blank group and the right picture is the model group;
[0031] Figure 8 The results of cell apoptosis rate detected by flow cytometry in Section 1.6 of Example 1;
[0032] Fig. 9 This is the position map of antigen-antibody binding detected after infection with DAPI in Section 1.7 of Example 1, where the left picture is the blank group and the right picture is the model group;
[0033] Fig.10 This is the location map of antigen-antibody binding detected after FITC infection in Section 1.7 of Example 1, where the left picture is the blank group and the right picture is the model group;
[0034] Fig.11 for Fig. 9 and Fig.10 Merged position map of the results;
[0035] Fig.12 The result graph of T4 and IL-6 content measured in Part 1.8 of Example 1, wherein "**" represents P < 0.05;
[0036] Fig.13 The results of the protection rate of Baihu decoction with different concentrations of crude drugs on different cells;
[0037] Fig.14The results of cell migration rate measured in Section 2.4 of Example 2;
[0038] Fig.15 The figure is the result of the effect of Baihu Decoction on the migration ability of thyroid follicular epithelial cells observed by inverted phase contrast microscopy in Part 2.4 of Example 2; wherein, from left to right, they are the results of the blank control group, the results of the model control group before adding Baihu Decoction, and the results of the model medication group after adding Baihu Decoction;
[0039] Fig.16 The cell morphology diagram of section 2.5 of Example 2 was observed after magnification of 200 times using an inverted phase contrast microscope, wherein the left diagram is the cell morphology diagram of the blank control group, and the right diagram is the cell morphology diagram of the model control group;
[0040] Fig.17 The cell morphology diagram of section 2.5 of Example 2 was observed after magnification of 400 times using an inverted phase contrast microscope, wherein the left diagram is the cell morphology diagram of the blank control group, and the right diagram is the cell morphology diagram of the model control group;
[0041] Fig.18 The cell morphology diagram of section 2.5 of Example 2 was observed after magnification of 200 times using an inverted phase contrast microscope, wherein the left diagram is the cell morphology diagram of the blank administration group, and the right diagram is the cell morphology diagram of the model administration group;
[0042] Fig.19 This is a diagram of cell apoptosis detected by flow cytometry in Section 2.6 of Example 2, wherein the left figure is the result of the blank group, and the right figure is the result of the model group;
[0043] Fig. 20 This is a diagram of cell apoptosis in the model drug administration group detected by flow cytometry in Section 2.6 of Example 2;
[0044] Fig.21 The cell apoptosis rate results obtained by analysis in Section 2.6 of Example 2;
[0045] Fig. 22 These are the results of T4 and IL-6 content in the cell supernatants of different groups obtained by ELISA in Part 2.7 of Example 2. DETAILED DESCRIPTION
[0046] The invention provides application of Baihu decoction in preparing medicine for treating Hashimoto's thyroiditis. The crude drug concentration of the Baihu decoction is 80-120 μg / ml.
[0047] In the present invention, the crude drug concentration of the Baihu Decoction is preferably 90-110 μg / ml, more preferably 95-105 μg / ml, and even more preferably 100 μg / ml. The Baihu Decoction is mainly used to treat Yangming Qi-divided heat syndrome, and is suitable for warm evil entering the Qi-divided or heat evil guest in the lung and stomach. The heat in the Qi-divided heat damages the body fluid, but it does not reach the Yangming Fu-divided, so it is best to clear away heat with pungent cold, and the composition is gypsum, rhizoma anemarrhenae, rice, and roasted licorice. Baihu Decoction is not a single treatment for Yangming. "Treatise on Febrile Diseases·Differentiation of Taiyang Disease Pulse and Symptoms and Treatment" says: "Typhoid fever, floating and slippery pulse, this is due to heat on the surface and cold inside, Baihu Decoction is the main treatment." This prescription is also suitable for exogenous cold evil, which enters the interior and turns into heat.
[0048] In the present invention, the Baihu decoction preferably includes the following raw material components in parts by weight: 10-15 parts of Anemarrhena, 30-35 parts of Gypsum, 3-5 parts of Licorice, and 10-15 parts of Polished Rice. The Anemarrhena is further preferably 12-14 parts, and more preferably 13 parts; the Gypsum is further preferably 32-34 parts, and more preferably 33 parts; the Licorice is further preferably 3.5-4.5 parts, and more preferably 4 parts; the Polished Rice is further preferably 12-14 parts, and more preferably 13 parts.
[0049] In the present invention, the preparation method of Baihu Decoction preferably comprises the following steps:
[0050] (1) Mixing Rhizoma Anemarrhenae, Gypsum, Licorice and glutinous rice, soaking them in water, and boiling them to obtain a primary extract and a medicinal residue;
[0051] (2) mixing the medicinal residue with water and decocting the mixture twice to obtain a decoction;
[0052] (3) The primary extract and the decoction are combined and concentrated to obtain a medicinal solution.
[0053] In the present invention, Rhizoma Anemarrhenae, Gypsum, Radix Glycyrrhizae and glutinous rice are mixed, soaked in water, and boiled to obtain primary extract and medicinal residues.
[0054] In the present invention, the amount of water added is preferably 7.5 to 10 times the mass of the impregnated medicinal material; the impregnation time is preferably 20 to 40 minutes, more preferably 25 to 35 minutes, and further preferably 30 minutes; the impregnation temperature is preferably 20 to 25°C, more preferably 22 to 24°C, and further preferably 23°C; the decoction time is preferably 50 to 70 minutes, more preferably 55 to 65 minutes, and further preferably 60 minutes; the decoction temperature is preferably 120 to 160°C, more preferably 125 to 155°C, further preferably 130 to 150°C, and further preferably 135 to 140°C.
[0055] In the present invention, the medicinal residues are mixed with water and decocted twice to obtain a decoction.
[0056] In the present invention, the volume ratio of the medicinal residue to water is preferably 1:2-3, more preferably 1:2.2-2.8, further preferably 1:2.4-2.6, and further preferably 1:2.5; the time for the secondary decoction is preferably 20-30 min, further preferably 22-28 min, further preferably 24-26 min, and further preferably 25 min; the temperature of the secondary decoction is preferably 90-110°C, further preferably 95-105°C, and further preferably 100°C; the purpose of the secondary decoction is to precipitate the remaining effective ingredients of the Chinese herbal medicine slices as much as possible.
[0057] In the present invention, the primary extract and the decoction are combined and concentrated to obtain a medicinal solution.
[0058] In the present invention, the concentration time is preferably 20 to 30 minutes, more preferably 22 to 28 minutes, more preferably 24 to 26 minutes, and further preferably 25 minutes; the concentration temperature is preferably 80 to 90°C, more preferably 82 to 88°C, more preferably 84 to 86°C, and further preferably 85°C; after the concentration, filtration treatment is preferably performed to remove impurities; the filtration method is preferably a negative pressure suction method.
[0059] The invention provides application of Baihu decoction in preparing medicine for treating thyroid cell damage.
[0060] In the present invention, the thyroid cells are thyroid follicular epithelial cells.
[0061] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0062] Example 1 Establishment of TgAb-induced thyroid follicular cell injury model
[0063] 1.1 Cell culture
[0064] Quickly take out the cryovial of Nthy-ori 3-1 cells (purchased from Guangzhou Jinio Biotechnology Co., Ltd.) from the liquid nitrogen tank, put the cryovial containing 1 ml of cell suspension into a 37°C water bath to thaw, wipe the surface of the cryovial with alcohol and move it into a clean bench, pipette the cell suspension into a 15 ml centrifuge tube, add 10 ml of RPMI-1640 culture medium (purchased from Gibco, USA), blow and mix, centrifuge at 1000r / min for 10min, discard the supernatant, add 9 ml of RPMI-1640 culture medium and blow evenly, add 1 ml of FBS, transfer all the cell suspension into a cell culture dish (purchased from Corning, USA), place it in a 37°C constant temperature cell culture incubator for culture, change the medium every other day, and observe the cell growth at any time.
[0065] After one day of cell recovery culture, observe the cell growth and change the medium. Put the cell culture dish into the clean bench and shake it crosswise to make the cells that were not firmly attached to the wall fall off. Aspirate the original culture medium, add 5ml RPMI-1640 culture medium and shake and wash twice, add 10ml complete culture medium containing 10% FBS, and place it in the incubator for culture.
[0066] 1.2 Effects of different concentrations on thyroid follicular epithelial cell injury model
[0067] Subculture the Nthy-ori 3-1 cells cultured in 1.1 and take 1×10 6 The cells were added into 20 ml of RPMI-1640 medium containing 10% fetal bovine serum (purchased from Gibco, USA) to obtain cell fluid. After the cell fluid was evenly pipetted, it was transferred to the sample loading tank. Each well contained 1×10 4 The cell fluid of cells was added to a 96-well plate and cultured in a carbon dioxide cell culture incubator for 24 h. The cell growth was observed and the 96-well plate was washed twice with 210 μl / well PBS every other day to avoid interference of the experiment caused by low-level antibodies contained in the complete culture medium.
[0068] A control group and a model group were set up in a 96-well plate. Each model group was added with 200 μl of RPMI-1640 medium containing different concentrations of TgAb: 1, 2, 4, 8, 16, and 32 ng / ml; the control group was added with 200 μl / well of RPMI-1640 medium (i.e., cells were grown under normal conditions); both the model group and the control group were placed in a carbon dioxide constant temperature incubator for 24 hours. On the second day, the cells in the wells were observed and the supernatant was removed. 100 μl of the pre-prepared 10% MTT working solution (Sigma, USA) was added to each well with a spray gun. After incubation in a constant temperature incubator for 3.5 hours, the supernatant was removed and 150 μl of DMSO solution (purchased from Beijing Solebow Technology Co., Ltd.) was added to each well. The wells were moved to a horizontal shaker and shaken for 20 minutes to completely dissolve the crystal violet. The absorbance OD value at 570 nm was measured with an enzyme marker to calculate the cell damage rate. The experiment was repeated 3 times. The calculation method is shown in formula (1). The results are shown in Tables 1 and Figure 1 shown.
[0069] Cell damage rate = (blank group OD value - model group OD value) / blank group OD value × 100% formula (1)
[0070] Table 1 The dose-effect relationship of different concentrations of TgAb on Nthy-ori 3-1 cell damage
[0071]
[0072] As shown in Table 1, the thyroid cell damage rate increased with the increase of TgAb concentration, showing a dose-effect dependence. When the concentration of TgAb solution was 8 ng / ml, the cell damage effect reached a plateau.
[0073] 1.3 Effects of different culture times on the thyroid follicular cell injury model
[0074] The experiment was conducted using the same experimental method as in 1.2, except that only the plateau concentration of 8 ng / ml was used as the model group. The viability of thyroid cells was tested at 6, 12, 24, 36, and 48 hours of culture. The results are shown in Table 2 and Figure 2 shown.
[0075] Table 2 Time-dependent relationship between TgAb and damage rate of Nthy-ori 3-1 cell model
[0076]
[0077] The results showed that TgAb tended to be stable after 24 hours of action on the thyroid cell model, and the difference between the model group and the control group was statistically significant, P<0.0001.
[0078] 1.4 Cell scratch assay
[0079] Use a marker to mark two parallel straight lines of moderate width on the bottom of each well of a 6-well plate. Subculture the Nthy-ori 3-1 cells cultured in 1.1 at a rate of 1×10 6 cells / well were inoculated into 6-well plates and cultured for 24 h to ensure that the cells covered 90% of the bottom of the dish. Each well was scratched with a 200 μl pipette tip, and the tip was evenly moved perpendicular to the thin line marked on the bottom of the dish. Each well was scratched twice. After scratching, the plates were washed twice with PBS to wash away the cells that fell off after mechanical damage.
[0080] A control group and a model group were set up, wherein 1 ml of RPMI-1640 medium was added to the control group; 1 ml of 8 ng / ml TgAb solution diluted with RPMI-1640 medium was added to the model group. Cell growth was observed and photographed at 0 and 24 h of culture, respectively, and the same scratch was taken at each time point as much as possible. Image J software was used to analyze and calculate the cell migration rate. The cell migration rate was calculated according to formula (2). The results are shown in Figure 3 , Figure 4 , Figure 5 shown.
[0081] Cell migration rate = (initial area - 24h area) / initial area × 100% Formula (2)
[0082] Depend on Figure 3-5 It can be seen that the scratch healing rate of the control group was 67.37% ± 0.025, and the scratch healing rate of the model group was 36.49% ± 0.021. Compared with the control group, the scratch healing rate of the model group was significantly reduced, and the difference was statistically significant P < 0.01. This result shows that TgAb can inhibit cell growth and tissue healing.
[0083] 1.5 Observation of cell morphology using an inverted phase contrast microscope
[0084] The Nthy-ori 3-1 cells in the logarithmic growth phase cultured in 1.1 were digested with 0.25% trypsin solution containing EDTA (purchased from Sigma, USA). After counting the cells, the cells were diluted to a cell density of 5×10 5 After preparing a cell suspension of 50 cells / ml, the cells were inoculated into a 6-well plate and incubated in a carbon dioxide constant temperature incubator for 24 h. The supernatant in the well plate was aspirated and the well plate was washed twice with PBS solution.
[0085] A "blank group" with 1 ml / well of RPMI-1640 medium and a "model group" with 1 ml / well of 8 ng / ml TgAb solution diluted with RPMI-1640 medium were set up. The 6-well plates of the blank group and the model group were placed in a constant temperature incubator for 24 hours, and then transferred to an inverted phase contrast microscope to observe the morphological changes of cells in each group and take photos for record. The results are shown in Figure 2. Figure 6 and Figure 7 shown.
[0086] It was found that the thyroid follicular cells in the "blank group" were mostly cubic, with smooth and intact cell membranes, clear boundaries, transparent cytoplasm, good adhesion to the wall, and normal nuclear division visible under a high-power microscope; while the thyroid follicular cells in the "model group" were cubic, oval or irregular, with blurred cell boundaries, little cytoplasm, poor adhesion to the wall, and cell vacuolation.
[0087] 1.6 Flow cytometry experiments
[0088] After observing the status of Nthy-ori 3-1 cells cultured in 1.1 using an inverted phase contrast microscope, the cells were centrifuged and counted, and 1 ml containing 1×10 6 cells were added to each well of a 6-well plate, and 100 μl of fetal bovine serum was added to each well. After gently shaking the 6-well plate, it was placed in a constant temperature incubator for 24 hours, and the cells were observed and washed with PBS for shaking. A blank group and a model group were set up, and 1 ml of RPMI-1640 medium without serum was added to the "blank group"; 1 ml of TgAb solution diluted with RPMI-1640 medium with a concentration of 8 ng / ml was added to the "model group". The 6-well plate was transferred to an incubator for 24 hours.
[0089] Subsequent experiments were performed according to the instructions of the AnnexinV-FITC / PI apoptosis detection kit (purchased from Hangzhou Lianke Biotechnology Co., Ltd.). Specifically, the cells were washed once with PBS, digested with 0.8 ml of EDTA-free trypsin digestion solution (EDTA may affect the binding of AnnexinV to phosphatidylserine), digestion was terminated, the cells were gently blown and centrifuged at 2000 r / min for 5 min, the cells were collected, the supernatant was discarded, the cells were resuspended twice with precooled 4 ml PBS, and 1-10×10 5 cells, centrifuge again and discard the supernatant, resuspend each group of cells in 500μl of 1× Binding Buffer into flow tubes, add 5μl AnnexinV-FITC dye to each flow tube, store at room temperature for 5min in the dark after resuspending, add 10μl PI to each tube, gently flick to mix, incubate at room temperature in the dark for 5min, and detect cell apoptosis rate by flow cytometer within 1h. The results are shown in Table 3 and Figure 8 shown.
[0090] Table 3 Flow cytometry double staining method to detect the damage rate of TgAb to the cell model at 8ng / ml
[0091]
[0092]
[0093] The results showed that compared with the "blank group" without TgAb treatment, the apoptosis of Nthy-ori 3-1 cells in the "model group" was significantly increased, indicating that TgAb promoted the apoptosis process of thyroid follicular cells and induced apoptotic damage.
[0094] 1.7 Indirect immunofluorescence
[0095] The Nthy-ori 3-1 cells in the logarithmic growth phase cultured in 1.1 were subcultured and 2×10 4 The cell suspension of cells was added dropwise on a clean coverslip of 24×24 mm, placed in a 6-well plate, and cultured in a constant temperature incubator for 24 h to allow the cells to grow well. After absorbing the supernatant, the cells were washed twice with PBS solution. 1 ml of tissue fixative (purchased from Wuhan Boster Biotechnology Co., Ltd.) was added to each experimental well of the six-well plate, and the cells were fixed for 10 min before being absorbed. PBS solution was added to wash twice and then absorbed. Then ready-to-use normal rabbit serum (purchased from Wuhan Boster Biotechnology Co., Ltd.) was fully added and blocked at 25°C for 30 min.
[0096] A blank group and a model group were set up. 1 ml of PBS solution was added to the wells of the blank group, and 1 ml of TgAb solution diluted with RPMI-1640 medium to obtain a concentration of 8 ng / ml was added to the wells of the model group. The wells were cultured overnight at 4°C. The next day, the cell well plate was placed on a decolorizing shaker and the slides were washed 3 times with PBS solution, each time for 5 minutes. After slightly drying, FITC-labeled rabbit anti-goat IgG antibody (purchased from Beijing Zhongshan Jinqiao Biotechnology Co., Ltd.) was added to the slides and covered, and incubated at room temperature for 50 minutes. Wash with PBS 3 times, 5 minutes / time, and after absorbing the excess liquid, DAPI stain (purchased from Wuhan Boster Biotechnology Co., Ltd.) was added to the cell slides, incubated at 25°C in the dark for 10 minutes, and the cell well plate was placed on a decolorizing shaker and the slides were washed 3 times with PBS solution, each time for 5 minutes. The cell slides were taken out of the 6-well plate, slightly dried, and sealed with PBS sealing medium (purchased from Wuhan Boster Biotechnology Co., Ltd.), and then placed on, and finally observed under a fluorescence microscope and collected and photographed. The results are as follows Fig. 9 , Fig.10 and Fig.11 shown.
[0097] Among them, the cell nucleus stained with DAPI appears blue under ultraviolet excitation, and the positively expressed FITC fluorescent marker emits green light.
[0098] Figure 9-11 The results showed that Tg antigen was expressed in the colloid of thyroid follicular cells, and the fluorescence signal labeled by FITC in the blank group was lower than that in the model group, indicating that TgAb promoted the production and secretion of Tg in thyroid follicular cells, and there was specific binding of Tg and TgAb during in vitro cell culture.
[0099] 1.8 Enzyme-linked immunosorbent assay
[0100] The Nthy-ori 3-1 cells cultured in 1.1 were subcultured and 1 ml of 1×10 6 cells, and add 100μl fetal bovine serum. After gently shaking the 6-well plate, place it in a constant temperature incubator for 24h and observe the cells; shake and wash with PBS. Add 1ml of RPMI-1640 medium without serum as the "blank group"; add 1ml of TgAb solution diluted with RPMI-1640 medium to obtain a concentration of 8ng / ml as the "model group". Transfer the 6-well plate to the incubator and culture for 24h. Take the cell supernatant and transfer it to 2ml EP tubes respectively. After centrifugation at 4℃ and 2500r / min for 20min, aspirate the supernatant into a new spare EP tube as a sample and store it in a -80℃ refrigerator.
[0101] Place the T4 and IL-6 enzyme-linked immunosorbent assay kits (purchased from Jiangsu Enzyme Immunity Industry Co., Ltd.) at 25°C for 30 minutes; operate in accordance with the instructions in the relevant manual. Among them, set up blank wells, standard wells, and sample wells to be tested, dilute the concentrated washing solution and the standard, add the sample, incubate, and wash (add enzyme-labeled reagent to the blank well without incubation and washing), add the color developer and mix, incubate at 37°C in the dark for 15 minutes, terminate the reaction with the stop solution, and finally adjust the blank well to zero, and quickly detect the absorbance OD value at a wavelength of 450nm within 15 minutes. According to the known concentration of the standard and the detected OD value, use Excel software to find the linear regression equation and calculate the sample concentration, and use GraphPadPrism 8 software for statistical analysis. The results are shown in Table 4 and Fig.12 shown.
[0102] Table 4 T4 and IL-6 content in the supernatant of thyroid follicular cells damaged by Tg antibodies
[0103]
[0104] The results showed that the T4 level in the model group was lower than that in the blank group, while the actual expression of IL-6 in the model group was significantly higher than that in the blank group, with a statistically significant difference of P<0.05. This indicated that TgAb treatment promoted the expression of inflammatory factors in thyroid follicular epithelial cells, induced inflammatory damage to thyroid follicular cells, and the cell model showed mild hypothyroidism.
[0105] In summary, TgAb can induce inflammatory damage such as proliferation inhibition and apoptosis in thyroid follicular epithelial cells Nthy-ori 3-1; through experiments, it was found that the inhibition of TgAb on the proliferation of thyroid follicular cells varies with time and antibody concentration, and the maximum inhibition rate can reach 80-90%. In the in vitro culture of monolayer cells without the formation of thyroid follicular functional structure, Tg is stored in thyroid follicular epithelial cells and has the ability to specifically bind to TgAb.
[0106] Example 2 Protective effect of Baihu decoction on thyroid follicular cells damaged by TgAb
[0107] 2.1 Preparation of Baihu Decoction
[0108] Weigh 12g of Rhizoma Anemarrhenae, 32g of Gypsum, 4g of Licorice, and 14g of Japonica Rice, mix them, place them in a clean beaker, add 600ml of ultrapure water, soak them at 25℃ for 30min, place the beaker soaked with medicine on an electric stove covered with asbestos net and heat it until the water boils, then adjust to a slow fire and continue to decoct for 1h (during this period, stir the bottom of the beaker with a glass rod) to collect the liquid medicine, add 200ml of ultrapure water, and repeat the decoction at 110℃ for 25min to precipitate the remaining effective ingredients of the Chinese medicine slices as much as possible, combine the liquid medicine obtained by the two decoctions, and concentrate it to a volume of 60ml at 85℃. Use four layers of gauze to cover the funnel, pour the liquid medicine on the top of the funnel, filter out impurities by negative pressure suction, and use a 50ml centrifuge tube to collect the remaining liquid medicine. Use a low-temperature high-speed centrifuge to centrifuge at 25℃ and 3000r / min for 25min, pour the obtained supernatant into an evaporating dish and vacuum dry for 24h, cover with plastic wrap, put the evaporating dish in a refrigerator at -20℃ for 12h, transfer to a low-temperature freeze dryer and freeze-dry into a crystalline powder, crush in the evaporating dish, scrape the powder into a 5ml EP tube, and place in the refrigerator for later use.
[0109] Weigh 1 g of drug powder using an electronic balance and put it into a 1.5 ml EP tube. Add 0.25 ml of RPMI-1640 culture medium and vortex to mix. The drug concentration is 4000 μg / ml. Filter the drug solution through a 0.22 μm micropore bacterial filter membrane into a new 1.5 ml EP tube and store in a refrigerator.
[0110] 2.2 MTT assay
[0111] The Nthy-ori 3-1 cells cultured in 1.1 were used as the experimental research object, and the MTT experiment was used to observe the effect of Baihu Decoction on the proliferation of Nthy-ori 3-1 cells under the condition of TgAb-induced Nthy-ori 3-1 cell damage. The details are as follows:
[0112] Observe the Nthy-ori 3-1 cells cultured in 1.1 using an inverted phase contrast microscope. When the cell morphology is good and the density reaches 80%, subculture the cells in the logarithmic growth phase. After counting the cells, add 200 μl of complete medium containing fetal bovine serum, 1×10 4 The cells / well were inoculated into a 96-well plate, and the plate was cultured in a cell culture incubator for 24 h. The supernatant was removed and the plate was washed twice with PBS at 210 μl / well (to avoid interference of the original low-level antibodies in the experiment).
[0113] The 96-well plate was divided into 4 groups from left to right: blank control group (added with RPMI-1640 medium), model control group (added with RPMI-1640 medium + TgAb), model drug group (added with RPMI-1640 medium + TgAb + Baihu Decoction), blank drug group (added with RPMI-1640 medium + Baihu Decoction), and 3 rows of duplicate wells were set in each group. The specific treatment method was as follows: 100 μl of RPMI-1640 medium was added to each well of the blank control group and the blank drug group; 100 μl of TgAb solution diluted with RPMI-1640 medium with a concentration of 8 ng / ml was added to each well of the model control group and the model drug group. After each group of solutions fully acted on the cells for 15 minutes, 100 μl of RPMI-1640 medium was added to each well of the blank control group and the model control group; 100 μl of Baihu Decoction with a crude drug concentration of 100 μg / ml was added to each well of the model drug group and the blank drug group. Place in a cell culture incubator for continued culture.
[0114] After 24 hours of incubation, the 96-well plate was taken out and placed under a microscope for observation. The plate was then transferred to a clean bench and the supernatant was discarded. 100 μl of the pre-prepared 10% MTT working solution was added to each well. The plate was incubated in the incubator for 3.5 hours. The MTT solution was discarded and 150 μl of DMSO solution was added to each well. The plate was moved to a horizontal shaker and shaken for 20 minutes to completely dissolve the crystal violet. The absorbance OD value at 570 nm was measured with an enzyme marker. The experiment was repeated 3 times. The cell protection rate of each group was calculated under the action of a drug concentration of 100 μg / ml. The calculation method is shown in formulas (3), (4), and (5). The results are shown in Table 5.
[0115] Blank medication group:
[0116] Drug protection rate = (blank medication group OD value - blank control group OD value) / blank control group OD value
[0117] ×100% formula (3);
[0118] Model drug administration group:
[0119] Drug protection rate = (OD value of model administration group - OD value of model control group) / OD value of model control group
[0120] ×100% formula (4);
[0121] The net protection rate of the model drug administration group = the drug protection rate of the model group - the drug protection rate of the blank group (formula (5)).
[0122] Table 5 Protection rate of Baihu decoction on model administration group and blank administration group
[0123]
[0124] The results showed that for Baihu decoction, the cell viability of the model administration group was better than that of the model control group (P<0.05), but lower than that of the blank control group; the cell viability of the blank administration group was different from that of the blank control group, but there was no significant change in viability; compared with the blank administration group, the cell viability protection effect of the model administration group was more obvious. That is, Baihu decoction can improve the damage of TgAb to thyroid follicular epithelial cells.
[0125] 2.3 The dose-effect relationship of Baihu decoction in relieving thyroid follicular cell damage
[0126] The maximum drug concentration of 400 μg / ml of Baihu decoction was used as the initial value, and gradient dilution was performed in sequence. The test was carried out according to the method in 2.2, and the drug dose-effect concentration curve was drawn using GraphPadPrism software. The results are shown in Table 6 and Fig.13 shown.
[0127] Table 6 The dose-effect relationship of different crude drug concentrations of Baihu Decoction on the protective effect of thyroid follicular cell injury model
[0128]
[0129] The results showed that Baihu Decoction could alleviate the proliferation damage of thyroid follicular cells induced by TgAb. At the same time, the optimal drug concentration of Baihu Decoction was selected as 100 μg / ml according to the protection rate and net protection rate of the model administration group.
[0130] 2.4 Cell scratch assay
[0131] The experiment was conducted using the method in 1.4, except that a blank control group, a model control group, and a model administration group were set up; the blank control group was added with 500 μl of RPMI-1640 medium twice; the model control group was added with 500 μl of 8 ng / ml TgAb solution diluted with RPMI-1640 medium, reacted for 15 min, and then 500 μl of RPMI-1640 medium was added; the model administration group was first added with 500 μl of 8 ng / ml TgAb solution diluted with RPMI-1640 medium, reacted for 15 min, and then 500 μl of Baihu decoction solution with a crude drug concentration of 100 μg / ml was added.
[0132] The results are as follows Fig.14 and Fig.15 shown.
[0133] The results showed that the wound healing rate in the model control group was 36.49±2.09%, and the wound healing rate in the model administration group with Baihu decoction was significantly reduced, with a statistically significant difference (P<0.01). This showed that Baihu decoction could alleviate the migration of damaged thyroid follicular cells, accelerate the disappearance of inflammation, and facilitate the development of tissue regeneration and repair.
[0134] 2.5 Observation of cell morphology using an inverted phase contrast microscope
[0135] The experiment was conducted using the method in 1.5, except that a "blank control group", "model control group", "model administration group" and "blank administration group" were set up (the treatment methods of each group were the same as those in section 2.2, except that the volume of RPMI-1640 culture medium was replaced with 500 μl). The results are shown in Fig.16 , Fig.17 , Fig.18 shown.
[0136] The results showed that compared with the blank control group, the blank administration group showed no significant changes in epithelial cell morphology, with clear cell boundaries and transparent cytoplasm. Compared with the cell morphology of the model control group, the cells in the model administration group were more stretched and irregular in shape. At the same time, compared with the blank administration group, the cell boundaries in the model administration group were unclear, the edges were blurred, the cytoplasm was less, there were bubble-like cell structure protrusions, and cell fragments were visible.
[0137] 2.6 Flow cytometry
[0138] The experiment was conducted using the method in Section 1.6, except that a model medication group was set up in addition to the blank group and the model group (the treatment method was the same as that of the model medication group in Section 2.4). The results are shown in Table 7 and Fig.19 , Fig. 20 , Fig.21 shown.
[0139] Table 7 Changes in cell model damage rate after Baihu Decoction
[0140]
[0141] Compared with the "blank group", the cell apoptosis rate in the "model group" was significantly increased, indicating that TgAb did induce excessive apoptosis of thyroid follicular cells; compared with the "blank group", the cell apoptosis rate in the "model medication group (Baihu Decoction)" did not change so significantly, indicating that the protective effect of Baihu Decoction on the TgAb-damaged thyroid follicular cell model may be partly due to the alleviation of cell apoptosis.
[0142] 2.7 Enzyme-linked immunosorbent assay
[0143] The experiment was conducted using the method in 1.8, except that a blank control group, a model control group and a model medication group (the treatment method of each group was the same as the treatment method in Section 2.4) were set up to replace the blank group and the model group, and the remaining treatments were the same as in Section 1.8 of Example 1.
[0144] The results are shown in Table 8 and Fig. 22 shown.
[0145] Table 8 ELISA method to detect the content of T4 and IL-6 in the cell supernatant after Baihu decoction
[0146]
[0147] ELISA test found that the supernatant content of T4 in the model administration group was higher than that in the model control group and lower than that in the blank control group; while the expression of inflammatory factor IL-6 in the model administration group was lower than that in the model control group. Baihu decoction can alleviate the inflammatory damage caused by overexpression of inflammatory factor IL-6 in the thyroid follicular cell injury model and regulate the secretion level of T4.
[0148] In summary, Baihu Decoction can alleviate TgAb-induced cell proliferation inhibition, apoptosis, cell migration and overexpression of inflammatory factors, and can regulate thyroxine levels, laying a foundation for the study of the mechanism of thyroid injury and providing a therapeutic basis for the selection and application of traditional Chinese medicine in Hashimoto's thyroiditis.
[0149] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. The use of Baihu decoction in preparing a medicine for treating Hashimoto's thyroiditis, characterized in that: The crude drug concentration of the Baihu decoction is 80-120 μg / ml.
2. The use according to claim 1, characterized in that: The Baihu decoction comprises the following raw material components in parts by weight: 10-15 parts of Anemarrhena asphodeloides, 30-35 parts of Gypsum, 3-5 parts of Licorice, and 10-15 parts of Japonica rice.
3. The use according to claim 1 or 2, characterized in that: The preparation method of the Baihu decoction comprises the following steps: (1) Mixing Rhizoma Anemarrhenae, Gypsum, Licorice and glutinous rice, soaking them in water, and boiling them to obtain a primary extract and a medicinal residue; (2) mixing the medicinal residue with water and decocting the mixture twice to obtain a decoction; (3) The primary extract and the decoction are combined and concentrated to obtain a medicinal solution.
4. The use according to claim 3, characterized in that: The amount of water added in step (1) is 7.5 to 10 times the weight of the impregnated medicinal material.
5. The use according to claim 3, characterized in that: The immersion time in step (1) is 20 to 40 minutes, and the immersion temperature is 20 to 25°C.
6. The use according to claim 3, characterized in that: The decocting time in step (1) is 50 to 70 minutes, and the decocting temperature is 120 to 160°C.
7. The use according to claim 3, characterized in that: In step (2), the volume ratio of the medicinal residue to water is 1:2-3.
8. The use according to claim 3, characterized in that: The time of the second decoction in step (2) is 20 to 30 minutes, and the temperature of the second decoction is 90 to 110°C.
9. The use according to claim 3, characterized in that: The concentration time in step (3) is 20 to 30 minutes, and the concentration temperature is 80 to 90°C.
10. Application of Baihu Decoction in the preparation of medicines for the treatment of thyroid cell damage.
